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compare return to baseline (RTB) for HRQoL. A seven point dif-
ference (considered to be clinically signiﬁcant) between baseline
and follow-up score was considered as RTB. RESULTS: ANOVA
indicated that RP group had higher scores for generic HRQoL
subscales of physical function (p = 0.019), role emotional (p =
0.037), vitality (p = 0.033) and general health (p = 0.05). Step-
wise log-linear regression models showed that RP was associated
with higher 12 month scores for most of the generic HRQoL
scales, bowel function (OR = 1.12), urinary bother (OR = 1.6)
and bowel bother (OR = 1.5). For generic HRQoL (SF-36) at 12
month follow-up, higher proportion of the RP group returned to
baseline on eight sub-scales. RP group had lower proportion
returning to baseline for urinary (p = 0.0012) and sexual (p =<
0.0001) functions, and higher proportion returning to baseline
for bowel function, urinary bother and bowel bother (p =<
0.005). Satisfaction with care was comparable between treat-
ment groups. CONCLUSIONS: Older patients appear to have
better tolerance for RP as indicated by patient reported 
outcomes. Thus age alone need not be a criterion in treatment
decision.
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OBJECTIVE: To compare self-reported satisfaction with care
and emotional well-being of newly diagnosed prostate cancer
(PCa) patients receiving either Radical Prostatectomy (RP) or
External Beam Radiation Therapy (EBRT). METHODS: The
study was part of a larger prospective cohort study. We recruited
231 newly diagnosed African-American and Caucasian PCa
patients from urology clinics of an urban academic hospital and
a VA hospital. Patients completed the Client Satisfaction Ques-
tionnaire (CSQ-8), SF-36, FACT-p and UCLA-PCI prior to their
treatment and at 3, 6, and 12 month follow-up. Demographic
and clinical data were obtained from hospital based databases.
Parametric and nonparametric tests were used to compare demo-
graphics, clinical characteristics and FACT-p subscales between
treatment groups. Log linear regression models were used to
assess factors associated with satisfaction. RESULTS: The RP
group was younger (p < 0.0001), had a higher proportion of
Caucasians (p < 0.0001), and were more like to be married (p <
0.0001), have incomes greater than $40,000 (p < 0.0001) and
be employed full-time (p < 0.0001). Gleason score, TNM stage
and Charlson comorbidity score were comparable by groups.
Higher number of EBRT group reported poorer outcome mea-
sures on emotional well being subscale of FACT-p, compared to
RP group. A higher proportion of RP patients indicated that they
were likely to recommend the treatment to a friend (p = 0.0244)
and that they would seek the same treatment if needed again 
(p = 0.0328). ANOVA of total CSQ8 score indicated signiﬁcant
differences between the groups and over time (p = 0.0059 and
0.0228, respectively). Log linear regression showed that RP
treatment (OR = 1.13, p = 0.045), baseline PSA (OR = 0.98, 
p = 0.0062) and VA hospital (OR = 0.84, p = 0.0299) were asso-
ciated with total satisfaction with care. CONCLUSION: EBRT,
higher baseline PSA and non-VA hospital type are associated
with lower satisfaction with care of PCa patients at 12 months
post-treatment.
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OBJECTIVE: Exploring impact of NSCLC on quality of life
(QOL) by eliciting utilities from a community sample. Non-small
cell lung cancer (NSCLC) and its treatment both have a sub-
stantial negative effect on QOL. Little published research quan-
tiﬁes these effects in advanced disease. METHODS: Health state
descriptions were developed from the literature and reﬁned
through clinician interviews (n = 6). Treatment response, stable
disease, progressed disease, near-death and adverse events (AEs):
neutropenia, febrile neutropenia, nausea, diarrhoea, stomatitis,
neuropathy and rash were described. The impact of oral versus
intravenous (IV) medication was also explored. A total of 154
lay people across the UK (Glasgow, Oxford, London, Cardiff)
were presented with information on NSCLC. Health states, pre-
sented randomly, were valued using the EQ-5D. These values
were converted to utilities for each health state. RESULTS: All
health states were associated with low utility values. The utility
value for near-death was the lowest (0.15) and that for treatment
response the highest (0.49). There was no statistical difference
between treatment response and stable disease (0.46). Stable
disease receiving IV therapy had a signiﬁcantly lower utility
(0.43) than stable disease with no treatment; stable disease
receiving oral therapy (0.45) did not. The utility value associated
with progressed disease (0.22) was closer to that for near-death.
Utilities for AEs were valued relative to the stable disease state.
The greatest disutility was associated with febrile neutropenia 
(−0.27) and the lowest with rash (−0.06). Disutilities associated
with other AEs were neuropathy (−0.15), neutropenia (−0.14),
nausea (−0.14), stomatitis (−0.14) and diarrhoea (−0.13). CON-
CLUSIONS: Societal valuation showed that all disease states and
AEs associated with NSCLC have a substantial impact on QOL,
with disease progression, febrile neutropenia and near-death
having the greatest impact. Treatment related rash is the least
serious adverse event. Stable disease is associated with a better
QOL than progressed disease.
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OBJECTIVES: Human Papillomavirus (HPV) is a necessary
cause of cervical cancer (CC). To date, CC screening programmes
have been the only tool to help to prevent CC by detecting and
removing precancerous lesions. With the expected licensure of a
quadrivalent HPV vaccination, a decision analysis model was
developed to quantify the health and economic beneﬁts of a
quadrivalent (6, 11, 16, 18) HPV vaccine alongside CC screen-
ing in Switzerland. METHODS: The vaccine was considered to
prevent 100% of HPV 6, 11, 16 and 18-associated diseases, with
lifetime duration of protection and 40% coverage rate, when
given to girls at age 12. Resource consumption included physi-
cian visits, medical examinations, treatments and hospitalisa-
tions. Data for management of abnormal pap smears, cervical
dysplasia and genital warts were estimated by Swiss experts.
